Just five months after the US Food and Drug Administration (FDA) granted "accelerated" approval for a drug to treat Alzheimer's disease , developed by Biogen and Eisai and called lecanemab, another pharmaceutical company, Eli Lilly, has released what it calls "positive results" from phase 3 trials for its own candidate Alzheimer's treatment, donanemab.
#people #effectively #significantly #participants #press-release #independently #world-health-organization #side-effects #web-browser #asymptomatic
[
add
]
[
|
|
...
]